CGT Potency Assays: Why Assay Development Is Critical to Cell & Gene Therapy Success
Capabilities
Understanding how to measure therapeutic impact is at the core of advancing cell and gene therapies. CGT potency assays are the cornerstone of this process—enabling developers to evaluate if a therapy is working as intended. In this insightful expert-led video, you’ll discover the strategic challenges and decision-making frameworks involved in potency assay development for complex therapies.
To explore how industry leaders are solving these challenges, register to watch the full presentation.
Unlock Insights from Industry Case Studies on CGT Potency Assays
This presentation offers an accessible look at how experienced CGT scientists approach potency validation from strategy to execution. You won’t get buried in data—instead, you’ll understand the frameworks, questions and design decisions shaping modern CGT potency assay development.
You’ll walk away knowing:
- What questions must be answered before selecting an assay platform
- Why multiple readouts are often required to confirm functionality
- Where surrogate systems play a role in complex disease models
- How quantitative methods like LC-MS/MS and ddPCR support reproducibility
Why Watch This Presentation?
If you’re working in cell and gene therapy R&D, quality, or regulatory affairs, this session will help you understand the non-obvious factors behind potency assay development. Whether you’re advancing a therapy into the clinic or refining your assay strategy post-Phase 1, this content helps you ask better questions and align your methods with biological function and regulatory standards.
Register to watch the full video and gain insight into how potency assays are developed to support clinical and commercial CGT products.
Meet our Presenter
Additional Resources
Learn about our IND Enabling Packages
Explore our CGT Webinar Series
